Dyadic InternationalDYAI
DYAI
About: Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Employees: 7
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
67% more capital invested
Capital invested by funds: $4.98M [Q3] → $8.33M (+$3.35M) [Q4]
20% more funds holding
Funds holding: 35 [Q3] → 42 (+7) [Q4]
1.08% more ownership
Funds ownership: 16.21% [Q3] → 17.3% (+1.08%) [Q4]
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
Research analyst outlook
We haven’t received any recent analyst ratings for DYAI.
Financial journalist opinion
Based on 4 articles about DYAI published over the past 30 days
Neutral
Seeking Alpha
6 days ago
Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript
Dyadic International, Inc. (NASDAQ:DYAI ) Q4 2024 Earnings Conference Call March 26, 2025 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President & Chief Executive Officer Joe Hazelton - Chief Operating Officer Conference Call Participants John Vandermosten - Zacks Small Capital Research Vernon Bernardino - HC Wainwright Dick Williams - Williams Resource Group Operator Good evening and welcome to Dyadic International's Year-End 2024 Conference Call. Currently, all participants are in a listen-only mode.
Neutral
GlobeNewsWire
1 week ago
Dyadic Reports 2024 Year-End Financial Results and Business Updates
JUPITER, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non- pharmaceutical applications including food, nutrition, and wellness, today announced its financial results for the full year 2024, highlighting significant progress in commercializing its proprietary Dapibus™ and C1 microbial protein production platforms and driving long-term growth opportunities.
Neutral
GlobeNewsWire
3 weeks ago
Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the year ended 2024 and host a corporate update conference call on Wednesday, March 26, 2025.
Neutral
GlobeNewsWire
3 weeks ago
Dyadic to Attend Multiple Industry Events in March
JUPITER, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced its management's participation in several prominent industry events worldwide.
Neutral
GlobeNewsWire
2 months ago
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
JUPITER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, provided an update on its business development efforts related to its Alternative Proteins business and emerging interest in leveraging the C1 platform in the diagnostic and vaccine space to address a variety of infectious diseases, such as the H5N1 Avian Influenza (“Bird Flu”) outbreak.
Neutral
GlobeNewsWire
4 months ago
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable Therapeutics Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable Therapeutics
Neutral
Seeking Alpha
4 months ago
Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript
Dyadic International, Inc. (NASDAQ:DYAI ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Ping Rawson - CFO Mark Emalfarb - President & CEO Joseph Hazelton - COO Patrick Lucy - Chairman Conference Call Participants John Vandermosten - Zacks Robert Hoffman - Princeton Opportunity Management Operator Operator Good evening, and welcome to Dyadic International Q3 2024 Conference Call. Currently, all participants are in a listen-only mode.
Neutral
GlobeNewsWire
4 months ago
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the third quarter 2024 and host a corporate update conference call on Tuesday, November 12, 2024.
Neutral
GlobeNewsWire
5 months ago
Dyadic Expands Global Presence with Participation in Key Industry Events
JUPITER, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the large-scale, efficient manufacturing of proteins for human and animal vaccines, therapeutics, and non-pharmaceutical applications, including food, nutrition, and wellness, today announced its participation in several prominent industry events worldwide.
Neutral
GlobeNewsWire
6 months ago
Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
JUPITER, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient, large-scale manufacture of proteins for use in non-pharmaceutical applications including food, nutrition and wellness, as well as animal and human health therapeutics and vaccines, today provided an update on business progress and announced its attendance at the Bioprocess International Conference in Boston, September 23-26, 2024.
Charts implemented using Lightweight Charts™